Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against AstraZeneca PLC due to allegations of securities law violations related to insurance fraud in China, which has led to significant legal exposure and a decline in stock value [2][4]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $50,000 in AstraZeneca between February 23, 2022, and December 17, 2024, to discuss their legal rights [1]. - A federal securities class action has been filed against AstraZeneca, with a deadline of February 21, 2025, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that AstraZeneca and its executives made false or misleading statements and failed to disclose significant legal risks associated with insurance fraud in China [4]. Group 2: Impact on Stock Performance - Following the announcement on October 30, 2024, regarding the cooperation of Leon Wang, AstraZeneca's China President, with Chinese authorities, the company's American Depositary Shares (ADS) fell by 3.1% [5]. - An article published on November 5, 2024, reported that dozens of senior executives at AstraZeneca China were implicated in an insurance fraud case, leading to a further decline of 7.2% in AstraZeneca's ADS [6]. Group 3: Whistleblower and Investor Information - Faruqi & Faruqi, LLP is also seeking information from whistleblowers, former employees, shareholders, and others regarding AstraZeneca's conduct [8].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of AstraZeneca PLC regarding a class action lawsuit alleging that the company made materially false and misleading statements and failed to disclose significant legal risks associated with its operations in China [1][2]. Summary by Relevant Sections Allegations - The lawsuit claims that AstraZeneca engaged in insurance fraud in China, leading to increased legal exposure and the detention of its China President by law enforcement [1]. - It is alleged that AstraZeneca understated its legal risks, which could materially harm its business activities in China once revealed [1]. - The defendants' statements regarding AstraZeneca's business, operations, and prospects are claimed to be materially false and misleading [1]. Class Period and Registration - The class period for the lawsuit is from February 23, 2022, to December 17, 2024 [1]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for February 21, 2025 [2]. Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [3].

Group 1 - The company reported Q4 revenues of $14.89 billion, representing a 25% year-on-year increase [1] - Operating profit for the quarter was $2 billion, up 79% compared to the previous year [1] - Earnings per share (EPS) reached $0.97, reflecting a 71% increase year-on-year [1] Group 2 - The investment group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts and buy/sell ratings [1] - The group offers detailed product sales forecasts and integrated financial statements for major pharmaceutical companies [1] - The lead consultant, Edmund Ingham, has extensive experience in biotech and healthcare, having compiled reports on over 1,000 companies [1]

Core Viewpoint - Healthcare companies exhibit low correlation with macroeconomic factors, making them an attractive investment option [1] Summary by Category - **Stock Prices**: The stock prices referenced were the afternoon prices on February 15, 2025, indicating a specific timeframe for the analysis [1] - **Publication Date**: The video discussing these insights was published on February 17, 2025, providing context for the timing of the information [1]

Product Pipeline and Development - AstraZeneca's product pipeline faces risks including potential delays in the delivery and launch of new medicines, which are critical for continued success[22]. - The company acknowledges that unexpected events could lead to failures in critical processes, impacting revenue and financial results[52]. - AstraZeneca has a robust development pipeline with multiple New Molecular Entities (NMEs) and significant indications under investigation, including oncology and rare diseases[111]. - The company is actively involved in research and development across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases[111]. - The company is focusing on expanding its oncology portfolio with novel therapies, including combinations with PD-1/TIGIT bispecific mAb[118]. - The company anticipates significant growth in its oncology segment, with several products in late-stage development[118]. - The company is committed to advancing its research and development efforts, with a focus on innovative therapies and combination treatments[118]. - The company has multiple ongoing clinical trials for new products, including Lynparza + Imfinzi for 1st-line ovarian cancer, which is expected to launch in Q2 2023[120]. - The company anticipates the launch of several products by 2026, including Orpathys + Imfinzi for 1st-line papillary renal cell carcinoma and Wainua for transthyretin-mediated amyloid cardiomyopathy[120]. - The company is developing new therapies for rare diseases, including Koselugo for neurofibromatosis type 1, which is currently submitted for approval[120]. - The company has a robust pipeline with multiple products in various stages of development, indicating a strong future growth potential[120]. Regulatory and Compliance Risks - The company emphasizes the importance of regulatory approvals, as delays could adversely affect revenue and increase costs due to post-approval requirements[29]. - Cybersecurity and data management are critical, as failures in these areas could lead to regulatory penalties and harm the company's reputation[49]. - AstraZeneca's reliance on data as a valuable commodity necessitates compliance with an increasing range of legislative and regulatory requirements[53]. - Non-compliance with privacy and AI-related laws could lead to material regulatory sanctions, reputational damage, and loss of stakeholder trust[59]. - Changes in data-related laws may require AstraZeneca and its vendors to alter business practices, potentially leading to substantial compliance costs[60]. - AstraZeneca is under scrutiny regarding its environmental targets and performance, with increasing pressure from investors and regulators[72]. Financial Performance and Sales - Calquence (acalabrutinib) sales in the US reached $2,190 million in 2024, up from $1,815 million in 2023, representing a growth of 20.7%[122]. - Imfinzi (durvalumab) generated $2,603 million in sales in the US for 2024, compared to $2,171 million in 2023, indicating a year-over-year increase of 19.8%[122]. - Tagrisso (osimertinib) sales in the US were $2,763 million in 2024, up from $2,276 million in 2023, reflecting a growth of 21.4%[122]. - Lynparza (olaparib) reported US sales of $1,332 million in 2024, an increase from $1,254 million in 2023, marking a growth of 6.2%[122]. - Enhertu (trastuzumab deruxtecan) achieved US sales of $545 million in 2024, significantly up from $261 million in 2023, showing a growth of 108.4%[122]. - The company anticipates continued growth in the oncology segment, with multiple products expected to drive revenue through 2035[122]. - Total Oncology sales reached $20,275 million, reflecting a 21% increase year-over-year[128]. - Tagrisso generated $6,580 million in sales, up 16%, with a notable 21% growth in the US market[128]. - Farxiga sales amounted to $7,656 million, a 31% increase, with a 28% growth in the US[128]. - Total Rare Disease sales reached $8,668 million, a 14% increase, with a 12% growth in the US[128]. - Total product sales decreased by 9% to $50,938 million, with a 16% decline in the US market[128]. - The company reported a 23% increase in Immunology sales, totaling $7,416 million[128]. - Total Product Sales in 2024 were $50,938 million, indicating strong underlying demand across key therapy areas[133]. Strategic Collaborations and Acquisitions - AstraZeneca's ongoing strategic collaborations and licensing arrangements are essential for expanding its product portfolio, although they carry inherent risks[24]. - The company has made strategic acquisitions, including the purchase of Alexion in 2021, to strengthen its pipeline and expand its market presence[101][106]. - AstraZeneca recorded $1,437 million in Alliance Revenue for 2024, up from $1,022 million in 2023 and $523 million in 2022, indicating a year-over-year growth of 40.7%[126]. - The geographical review indicates a focus on expanding market presence in the US, China, and EU, with specific strategies for product launches and collaborations[127]. Market Challenges and Risks - The company faces challenges in emerging markets, including pricing affordability and competitive pressures, which could affect its business operations[32]. - AstraZeneca is heavily reliant on third-party suppliers for critical operations, and any disruptions could materially affect its reputation and financial condition[41]. - The pharmaceutical industry is experiencing pressure to limit IP protections, which could impact AstraZeneca's revenue from patented products[80]. - The company faces risks associated with data privacy, cybersecurity, and intellectual property as it increases its use of AI technologies[57]. - Changes in tax treaties or tax laws could materially adversely affect AstraZeneca's financial position and cash tax liabilities[97][98]. - AstraZeneca's patent expiry for key products is under scrutiny, with ongoing proceedings affecting revenue projections[125].

What science can do AstraZeneca Annual Report and Form 20-F Information 2024 Welcome What science can do We are a global, science-led, patient-focused pharmaceutical business, committed to excellence in the research, development and commercialisation of prescription medicines. We aim to transform the lives of patients with improved outcomes and a better quality of life. Our sustainability reporting Our sustainability reporting is prepared in line with the UK Companies Act 2006, sections 414CA and 414CB. In ...

NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/astrazeneca-plc-l ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased AstraZeneca PLC securities between February 23, 2022, and December 17, 2024, about the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased AstraZeneca securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 21, 2025 [3] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that AstraZeneca made materially false and misleading statements, including engaging in insurance fraud in China and facing heightened legal exposure as a result [5] - The allegations suggest that AstraZeneca understated its legal risks, which could materially harm its business activities in China once revealed [5]

Core Viewpoint - Rosen Law Firm is reminding purchasers of AstraZeneca PLC securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the AstraZeneca securities class action is from February 23, 2022, to December 17, 2024 [1]. - Investors who purchased AstraZeneca securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 21, 2025 [3]. Group 2: Legal Allegations - The lawsuit alleges that AstraZeneca made materially false and misleading statements and failed to disclose significant issues, including engaging in insurance fraud in China [5]. - As a result of these actions, AstraZeneca faced increased legal exposure in China, leading to the detention of its China President by law enforcement [5]. - The lawsuit claims that the true details, once revealed, could materially harm AstraZeneca's business activities in China, resulting in damages to investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].

Vertex Pharmaceuticals (VRTX -0.77%) and AstraZeneca (AZN -1.17%), two of the world's leading drugmakers, missed last year's strong market rally. Both finished 2024 slightly in the red. They're already doing better in 2025, though. And there are good reasons to think both could maintain a strong performance throughout the year. Here's why. 1. Vertex PharmaceuticalsVertex Pharmaceuticals performed well for much of 2024. The stock slid during the year's final months, culminating in a massive one-day drop prom ...